StockWatch: Novo’s 2030 Strategy Underwhelms Investors at Capital Markets Day

Novo Nordisk presented its 2030 strategy at a Capital Markets Day, aiming to launch “more than five multi-blockbusters” — drugs with multiple billions of dollars in annual sales — every year through 2030. The company also projected more than DKK 150 billion (just over $23 billion) in risk-adjusted pipeline sales by 2035.

Investors were underwhelmed by the targets, suggesting the strategy did not meet expectations for Novo’s growth outlook.